{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "a4421442-d6d0-4ca5-b9bd-32fd91efb150",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "a9054c2f-49ff-499b-a623-977a298da5e5",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.read_csv(\"CancerClinicalTrialData.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "b2ac41dd-fb26-493e-8bc3-7665aed4c142",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_cancer = df[df['Conditions'].str.contains('Cancer')]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "7b21fe19-d7be-4fd9-ae54-3e99de2c89f2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>Title</th>\n",
       "      <th>Status</th>\n",
       "      <th>Study Results</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Outcome Measures</th>\n",
       "      <th>Gender</th>\n",
       "      <th>Age</th>\n",
       "      <th>Phases</th>\n",
       "      <th>Enrollment</th>\n",
       "      <th>Funded Bys</th>\n",
       "      <th>Study Designs</th>\n",
       "      <th>Start Date</th>\n",
       "      <th>Completion Date</th>\n",
       "      <th>Study Duration (months)</th>\n",
       "      <th>Locations</th>\n",
       "      <th>URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Immediate-Release Oxycodone Capsules Study in ...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>Drug: Oxycodone|Drug: Morphine</td>\n",
       "      <td>Numerical Rating Scale (NRS)|The Average Dose ...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years to 80 Years   (Adult, Older Adult)</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>242</td>\n",
       "      <td>Industry</td>\n",
       "      <td>Allocation: Randomized|Intervention Model: Par...</td>\n",
       "      <td>Jan-11</td>\n",
       "      <td>Jul-12</td>\n",
       "      <td>18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01675622</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>A Phase II Study of Nivolumab in Combination W...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>Drug: Nivolumab|Drug: Cabozantinib</td>\n",
       "      <td>Overall Response Rate|Number of Participants W...</td>\n",
       "      <td>Female</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>18</td>\n",
       "      <td>Other|Industry</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>30-Nov-17</td>\n",
       "      <td>30-Aug-19</td>\n",
       "      <td>21</td>\n",
       "      <td>Dana-Farber Cancer Institute, Boston, Massachu...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03316586</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Radiation, Cetuximab and Pemetrexed With or Wi...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>Drug: Bevacizumab|Drug: Cetuximab|Drug: Pemetr...</td>\n",
       "      <td>2-year Progression-free Survival (PFS)|2-year ...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>80</td>\n",
       "      <td>Other|Industry</td>\n",
       "      <td>Allocation: Randomized|Intervention Model: Sin...</td>\n",
       "      <td>Oct-08</td>\n",
       "      <td>Sep-14</td>\n",
       "      <td>71</td>\n",
       "      <td>University of Pittsburgh Medical Center, Pitts...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00703976</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Fulvestrant Plus Enzalutamide in ER+/Her2- Adv...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>Drug: Fulvestrant with Enzalutamide</td>\n",
       "      <td>Clinical Benefit Rate of the Combination of En...</td>\n",
       "      <td>Female</td>\n",
       "      <td>18 Years to 100 Years   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>32</td>\n",
       "      <td>Other|U.S. Fed</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>6-Jul-17</td>\n",
       "      <td>10-Apr-20</td>\n",
       "      <td>33</td>\n",
       "      <td>University of Colorado, Aurora, Colorado, Unit...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT02953860</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>PROspective Non-interventional Open laBEl Tria...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>Drug: Oxycodone/Naloxone</td>\n",
       "      <td>Change in Numeric Rating Scales (NRS) Score|Ch...</td>\n",
       "      <td>All</td>\n",
       "      <td>20 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 4</td>\n",
       "      <td>359</td>\n",
       "      <td>Industry</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Jul-12</td>\n",
       "      <td>Apr-14</td>\n",
       "      <td>21</td>\n",
       "      <td>13 sites including Yeungnam University Medical...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01719757</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11183</th>\n",
       "      <td>11184</td>\n",
       "      <td>A Phase II Study of Bintrafusp Alfa (M7824) in...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Urothelial Cancer</td>\n",
       "      <td>Drug: Bintrafusp alfa (M7824)</td>\n",
       "      <td>Proportion of Participants With an Objective R...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>26-Oct-20</td>\n",
       "      <td>13-Oct-21</td>\n",
       "      <td>11</td>\n",
       "      <td>National Institutes of Health Clinical Center,...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT04501094</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11186</th>\n",
       "      <td>11187</td>\n",
       "      <td>BN-Brachyury, Entinostat, Adotrastuzumab Emtan...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Breast Cancer|Triple Negative Breast Cancer|HE...</td>\n",
       "      <td>Biological: Brachyury-TRICOM|Drug: Entinostat|...</td>\n",
       "      <td>Overall Response (Partial Response + Complete ...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>4-May-21</td>\n",
       "      <td>22-Oct-21</td>\n",
       "      <td>5</td>\n",
       "      <td>National Institutes of Health Clinical Center,...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT04296942</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11190</th>\n",
       "      <td>11191</td>\n",
       "      <td>BrUOG 337: Olaparib Prior to Radical Prostatec...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Prostate Cancer|Adenocarcinoma of the Prostate</td>\n",
       "      <td>Drug: Olaparib Pill|Procedure: Prostatectomy</td>\n",
       "      <td>Number of Participants With Prostate Specific ...</td>\n",
       "      <td>Male</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>Other|Industry</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>25-May-18</td>\n",
       "      <td>7-Dec-21</td>\n",
       "      <td>42</td>\n",
       "      <td>Lifespan Cancer Institute: The Miriam and Rhod...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03432897</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11193</th>\n",
       "      <td>11194</td>\n",
       "      <td>Immune Checkpoint Inhibitor M7824 and the Immu...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Histologically or Cytologically Confirmed Panc...</td>\n",
       "      <td>Drug: M7824|Drug: M9241|Radiation: SBRT</td>\n",
       "      <td>Recommended Phase 2 Dose (RP2D) of NHS-IL12 (M...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 1|Phase 2</td>\n",
       "      <td>3</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>15-Jun-21</td>\n",
       "      <td>3-Feb-22</td>\n",
       "      <td>7</td>\n",
       "      <td>National Institutes of Health Clinical Center,...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT04327986</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11194</th>\n",
       "      <td>11195</td>\n",
       "      <td>Study of Euthyroid Hypothyroxinemia in Metasta...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Metastatic Breast Cancer|Thyroid Dysfunction</td>\n",
       "      <td>Drug: Triiodothyronine (T3)</td>\n",
       "      <td>Number of Participants With Progression-free S...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years to 105 Years   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>7</td>\n",
       "      <td>Other</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>1-Mar-19</td>\n",
       "      <td>9-Mar-22</td>\n",
       "      <td>36</td>\n",
       "      <td>Aultman Medical Group Hematology and Oncology,...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03787303</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>4839 rows × 18 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        Rank                                              Title      Status  \\\n",
       "0          1  Immediate-Release Oxycodone Capsules Study in ...   Completed   \n",
       "1          2  A Phase II Study of Nivolumab in Combination W...   Completed   \n",
       "2          3  Radiation, Cetuximab and Pemetrexed With or Wi...   Completed   \n",
       "3          4  Fulvestrant Plus Enzalutamide in ER+/Her2- Adv...   Completed   \n",
       "4          5  PROspective Non-interventional Open laBEl Tria...   Completed   \n",
       "...      ...                                                ...         ...   \n",
       "11183  11184  A Phase II Study of Bintrafusp Alfa (M7824) in...  Terminated   \n",
       "11186  11187  BN-Brachyury, Entinostat, Adotrastuzumab Emtan...  Terminated   \n",
       "11190  11191  BrUOG 337: Olaparib Prior to Radical Prostatec...  Terminated   \n",
       "11193  11194  Immune Checkpoint Inhibitor M7824 and the Immu...  Terminated   \n",
       "11194  11195  Study of Euthyroid Hypothyroxinemia in Metasta...  Terminated   \n",
       "\n",
       "      Study Results                                         Conditions  \\\n",
       "0       Has Results                                             Cancer   \n",
       "1       Has Results                                      Breast Cancer   \n",
       "2       Has Results                                             Cancer   \n",
       "3       Has Results                                      Breast Cancer   \n",
       "4       Has Results                                             Cancer   \n",
       "...             ...                                                ...   \n",
       "11183   Has Results                                  Urothelial Cancer   \n",
       "11186   Has Results  Breast Cancer|Triple Negative Breast Cancer|HE...   \n",
       "11190   Has Results     Prostate Cancer|Adenocarcinoma of the Prostate   \n",
       "11193   Has Results  Histologically or Cytologically Confirmed Panc...   \n",
       "11194   Has Results       Metastatic Breast Cancer|Thyroid Dysfunction   \n",
       "\n",
       "                                           Interventions  \\\n",
       "0                         Drug: Oxycodone|Drug: Morphine   \n",
       "1                     Drug: Nivolumab|Drug: Cabozantinib   \n",
       "2      Drug: Bevacizumab|Drug: Cetuximab|Drug: Pemetr...   \n",
       "3                    Drug: Fulvestrant with Enzalutamide   \n",
       "4                               Drug: Oxycodone/Naloxone   \n",
       "...                                                  ...   \n",
       "11183                      Drug: Bintrafusp alfa (M7824)   \n",
       "11186  Biological: Brachyury-TRICOM|Drug: Entinostat|...   \n",
       "11190       Drug: Olaparib Pill|Procedure: Prostatectomy   \n",
       "11193            Drug: M7824|Drug: M9241|Radiation: SBRT   \n",
       "11194                        Drug: Triiodothyronine (T3)   \n",
       "\n",
       "                                        Outcome Measures  Gender  \\\n",
       "0      Numerical Rating Scale (NRS)|The Average Dose ...     All   \n",
       "1      Overall Response Rate|Number of Participants W...  Female   \n",
       "2      2-year Progression-free Survival (PFS)|2-year ...     All   \n",
       "3      Clinical Benefit Rate of the Combination of En...  Female   \n",
       "4      Change in Numeric Rating Scales (NRS) Score|Ch...     All   \n",
       "...                                                  ...     ...   \n",
       "11183  Proportion of Participants With an Objective R...     All   \n",
       "11186  Overall Response (Partial Response + Complete ...     All   \n",
       "11190  Number of Participants With Prostate Specific ...    Male   \n",
       "11193  Recommended Phase 2 Dose (RP2D) of NHS-IL12 (M...     All   \n",
       "11194  Number of Participants With Progression-free S...     All   \n",
       "\n",
       "                                                Age           Phases  \\\n",
       "0       18 Years to 80 Years   (Adult, Older Adult)          Phase 3   \n",
       "1         18 Years and older   (Adult, Older Adult)          Phase 2   \n",
       "2         18 Years and older   (Adult, Older Adult)          Phase 2   \n",
       "3      18 Years to 100 Years   (Adult, Older Adult)          Phase 2   \n",
       "4         20 Years and older   (Adult, Older Adult)          Phase 4   \n",
       "...                                             ...              ...   \n",
       "11183     18 Years and older   (Adult, Older Adult)          Phase 2   \n",
       "11186     18 Years and older   (Adult, Older Adult)          Phase 1   \n",
       "11190     18 Years and older   (Adult, Older Adult)          Phase 2   \n",
       "11193     18 Years and older   (Adult, Older Adult)  Phase 1|Phase 2   \n",
       "11194  18 Years to 105 Years   (Adult, Older Adult)          Phase 2   \n",
       "\n",
       "       Enrollment      Funded Bys  \\\n",
       "0             242        Industry   \n",
       "1              18  Other|Industry   \n",
       "2              80  Other|Industry   \n",
       "3              32  Other|U.S. Fed   \n",
       "4             359        Industry   \n",
       "...           ...             ...   \n",
       "11183           2             NIH   \n",
       "11186           1             NIH   \n",
       "11190           1  Other|Industry   \n",
       "11193           3             NIH   \n",
       "11194           7           Other   \n",
       "\n",
       "                                           Study Designs Start Date  \\\n",
       "0      Allocation: Randomized|Intervention Model: Par...     Jan-11   \n",
       "1      Allocation: N/A|Intervention Model: Single Gro...  30-Nov-17   \n",
       "2      Allocation: Randomized|Intervention Model: Sin...     Oct-08   \n",
       "3      Allocation: N/A|Intervention Model: Single Gro...   6-Jul-17   \n",
       "4      Allocation: N/A|Intervention Model: Single Gro...     Jul-12   \n",
       "...                                                  ...        ...   \n",
       "11183  Allocation: N/A|Intervention Model: Single Gro...  26-Oct-20   \n",
       "11186  Allocation: Non-Randomized|Intervention Model:...   4-May-21   \n",
       "11190  Allocation: N/A|Intervention Model: Single Gro...  25-May-18   \n",
       "11193  Allocation: Non-Randomized|Intervention Model:...  15-Jun-21   \n",
       "11194  Allocation: N/A|Intervention Model: Single Gro...   1-Mar-19   \n",
       "\n",
       "      Completion Date  Study Duration (months)  \\\n",
       "0              Jul-12                       18   \n",
       "1           30-Aug-19                       21   \n",
       "2              Sep-14                       71   \n",
       "3           10-Apr-20                       33   \n",
       "4              Apr-14                       21   \n",
       "...               ...                      ...   \n",
       "11183       13-Oct-21                       11   \n",
       "11186       22-Oct-21                        5   \n",
       "11190        7-Dec-21                       42   \n",
       "11193        3-Feb-22                        7   \n",
       "11194        9-Mar-22                       36   \n",
       "\n",
       "                                               Locations  \\\n",
       "0                                                    NaN   \n",
       "1      Dana-Farber Cancer Institute, Boston, Massachu...   \n",
       "2      University of Pittsburgh Medical Center, Pitts...   \n",
       "3      University of Colorado, Aurora, Colorado, Unit...   \n",
       "4      13 sites including Yeungnam University Medical...   \n",
       "...                                                  ...   \n",
       "11183  National Institutes of Health Clinical Center,...   \n",
       "11186  National Institutes of Health Clinical Center,...   \n",
       "11190  Lifespan Cancer Institute: The Miriam and Rhod...   \n",
       "11193  National Institutes of Health Clinical Center,...   \n",
       "11194  Aultman Medical Group Hematology and Oncology,...   \n",
       "\n",
       "                                               URL  \n",
       "0      https://ClinicalTrials.gov/show/NCT01675622  \n",
       "1      https://ClinicalTrials.gov/show/NCT03316586  \n",
       "2      https://ClinicalTrials.gov/show/NCT00703976  \n",
       "3      https://ClinicalTrials.gov/show/NCT02953860  \n",
       "4      https://ClinicalTrials.gov/show/NCT01719757  \n",
       "...                                            ...  \n",
       "11183  https://ClinicalTrials.gov/show/NCT04501094  \n",
       "11186  https://ClinicalTrials.gov/show/NCT04296942  \n",
       "11190  https://ClinicalTrials.gov/show/NCT03432897  \n",
       "11193  https://ClinicalTrials.gov/show/NCT04327986  \n",
       "11194  https://ClinicalTrials.gov/show/NCT03787303  \n",
       "\n",
       "[4839 rows x 18 columns]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_cancer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "86996f2d-356a-4ede-9f45-ddad1149718c",
   "metadata": {},
   "outputs": [],
   "source": [
    "name = df_cancer['Study Designs'][123]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "f2b0a562-556d-4ab2-b709-ee2c6c0d5ad2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment'"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "name"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "b682ebb9-2e4e-493b-bbee-71f8002617d2",
   "metadata": {},
   "outputs": [],
   "source": [
    "A = []\n",
    "for item in df_cancer['Study Designs']:\n",
    "    A.append(item.split()[-1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "c9aed265-ce54-4781-97a8-458d6ce0662f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "4839"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(A)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "929019b5-264c-4900-aded-4403be3e6c39",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_cancer1 = df_cancer.copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "eb6073a4-4951-4eac-bd87-22fdc02ea2fa",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>Title</th>\n",
       "      <th>Status</th>\n",
       "      <th>Study Results</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Outcome Measures</th>\n",
       "      <th>Gender</th>\n",
       "      <th>Age</th>\n",
       "      <th>Phases</th>\n",
       "      <th>Enrollment</th>\n",
       "      <th>Funded Bys</th>\n",
       "      <th>Study Designs</th>\n",
       "      <th>Start Date</th>\n",
       "      <th>Completion Date</th>\n",
       "      <th>Study Duration (months)</th>\n",
       "      <th>Locations</th>\n",
       "      <th>URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Immediate-Release Oxycodone Capsules Study in ...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>Drug: Oxycodone|Drug: Morphine</td>\n",
       "      <td>Numerical Rating Scale (NRS)|The Average Dose ...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years to 80 Years   (Adult, Older Adult)</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>242</td>\n",
       "      <td>Industry</td>\n",
       "      <td>Allocation: Randomized|Intervention Model: Par...</td>\n",
       "      <td>Jan-11</td>\n",
       "      <td>Jul-12</td>\n",
       "      <td>18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01675622</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>A Phase II Study of Nivolumab in Combination W...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>Drug: Nivolumab|Drug: Cabozantinib</td>\n",
       "      <td>Overall Response Rate|Number of Participants W...</td>\n",
       "      <td>Female</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>18</td>\n",
       "      <td>Other|Industry</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>30-Nov-17</td>\n",
       "      <td>30-Aug-19</td>\n",
       "      <td>21</td>\n",
       "      <td>Dana-Farber Cancer Institute, Boston, Massachu...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03316586</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Radiation, Cetuximab and Pemetrexed With or Wi...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>Drug: Bevacizumab|Drug: Cetuximab|Drug: Pemetr...</td>\n",
       "      <td>2-year Progression-free Survival (PFS)|2-year ...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>80</td>\n",
       "      <td>Other|Industry</td>\n",
       "      <td>Allocation: Randomized|Intervention Model: Sin...</td>\n",
       "      <td>Oct-08</td>\n",
       "      <td>Sep-14</td>\n",
       "      <td>71</td>\n",
       "      <td>University of Pittsburgh Medical Center, Pitts...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00703976</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Fulvestrant Plus Enzalutamide in ER+/Her2- Adv...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>Drug: Fulvestrant with Enzalutamide</td>\n",
       "      <td>Clinical Benefit Rate of the Combination of En...</td>\n",
       "      <td>Female</td>\n",
       "      <td>18 Years to 100 Years   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>32</td>\n",
       "      <td>Other|U.S. Fed</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>6-Jul-17</td>\n",
       "      <td>10-Apr-20</td>\n",
       "      <td>33</td>\n",
       "      <td>University of Colorado, Aurora, Colorado, Unit...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT02953860</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>PROspective Non-interventional Open laBEl Tria...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>Drug: Oxycodone/Naloxone</td>\n",
       "      <td>Change in Numeric Rating Scales (NRS) Score|Ch...</td>\n",
       "      <td>All</td>\n",
       "      <td>20 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 4</td>\n",
       "      <td>359</td>\n",
       "      <td>Industry</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Jul-12</td>\n",
       "      <td>Apr-14</td>\n",
       "      <td>21</td>\n",
       "      <td>13 sites including Yeungnam University Medical...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01719757</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11183</th>\n",
       "      <td>11184</td>\n",
       "      <td>A Phase II Study of Bintrafusp Alfa (M7824) in...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Urothelial Cancer</td>\n",
       "      <td>Drug: Bintrafusp alfa (M7824)</td>\n",
       "      <td>Proportion of Participants With an Objective R...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>26-Oct-20</td>\n",
       "      <td>13-Oct-21</td>\n",
       "      <td>11</td>\n",
       "      <td>National Institutes of Health Clinical Center,...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT04501094</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11186</th>\n",
       "      <td>11187</td>\n",
       "      <td>BN-Brachyury, Entinostat, Adotrastuzumab Emtan...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Breast Cancer|Triple Negative Breast Cancer|HE...</td>\n",
       "      <td>Biological: Brachyury-TRICOM|Drug: Entinostat|...</td>\n",
       "      <td>Overall Response (Partial Response + Complete ...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>4-May-21</td>\n",
       "      <td>22-Oct-21</td>\n",
       "      <td>5</td>\n",
       "      <td>National Institutes of Health Clinical Center,...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT04296942</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11190</th>\n",
       "      <td>11191</td>\n",
       "      <td>BrUOG 337: Olaparib Prior to Radical Prostatec...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Prostate Cancer|Adenocarcinoma of the Prostate</td>\n",
       "      <td>Drug: Olaparib Pill|Procedure: Prostatectomy</td>\n",
       "      <td>Number of Participants With Prostate Specific ...</td>\n",
       "      <td>Male</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>Other|Industry</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>25-May-18</td>\n",
       "      <td>7-Dec-21</td>\n",
       "      <td>42</td>\n",
       "      <td>Lifespan Cancer Institute: The Miriam and Rhod...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03432897</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11193</th>\n",
       "      <td>11194</td>\n",
       "      <td>Immune Checkpoint Inhibitor M7824 and the Immu...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Histologically or Cytologically Confirmed Panc...</td>\n",
       "      <td>Drug: M7824|Drug: M9241|Radiation: SBRT</td>\n",
       "      <td>Recommended Phase 2 Dose (RP2D) of NHS-IL12 (M...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 1|Phase 2</td>\n",
       "      <td>3</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>15-Jun-21</td>\n",
       "      <td>3-Feb-22</td>\n",
       "      <td>7</td>\n",
       "      <td>National Institutes of Health Clinical Center,...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT04327986</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11194</th>\n",
       "      <td>11195</td>\n",
       "      <td>Study of Euthyroid Hypothyroxinemia in Metasta...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Metastatic Breast Cancer|Thyroid Dysfunction</td>\n",
       "      <td>Drug: Triiodothyronine (T3)</td>\n",
       "      <td>Number of Participants With Progression-free S...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years to 105 Years   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>7</td>\n",
       "      <td>Other</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>1-Mar-19</td>\n",
       "      <td>9-Mar-22</td>\n",
       "      <td>36</td>\n",
       "      <td>Aultman Medical Group Hematology and Oncology,...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03787303</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>4839 rows × 18 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        Rank                                              Title      Status  \\\n",
       "0          1  Immediate-Release Oxycodone Capsules Study in ...   Completed   \n",
       "1          2  A Phase II Study of Nivolumab in Combination W...   Completed   \n",
       "2          3  Radiation, Cetuximab and Pemetrexed With or Wi...   Completed   \n",
       "3          4  Fulvestrant Plus Enzalutamide in ER+/Her2- Adv...   Completed   \n",
       "4          5  PROspective Non-interventional Open laBEl Tria...   Completed   \n",
       "...      ...                                                ...         ...   \n",
       "11183  11184  A Phase II Study of Bintrafusp Alfa (M7824) in...  Terminated   \n",
       "11186  11187  BN-Brachyury, Entinostat, Adotrastuzumab Emtan...  Terminated   \n",
       "11190  11191  BrUOG 337: Olaparib Prior to Radical Prostatec...  Terminated   \n",
       "11193  11194  Immune Checkpoint Inhibitor M7824 and the Immu...  Terminated   \n",
       "11194  11195  Study of Euthyroid Hypothyroxinemia in Metasta...  Terminated   \n",
       "\n",
       "      Study Results                                         Conditions  \\\n",
       "0       Has Results                                             Cancer   \n",
       "1       Has Results                                      Breast Cancer   \n",
       "2       Has Results                                             Cancer   \n",
       "3       Has Results                                      Breast Cancer   \n",
       "4       Has Results                                             Cancer   \n",
       "...             ...                                                ...   \n",
       "11183   Has Results                                  Urothelial Cancer   \n",
       "11186   Has Results  Breast Cancer|Triple Negative Breast Cancer|HE...   \n",
       "11190   Has Results     Prostate Cancer|Adenocarcinoma of the Prostate   \n",
       "11193   Has Results  Histologically or Cytologically Confirmed Panc...   \n",
       "11194   Has Results       Metastatic Breast Cancer|Thyroid Dysfunction   \n",
       "\n",
       "                                           Interventions  \\\n",
       "0                         Drug: Oxycodone|Drug: Morphine   \n",
       "1                     Drug: Nivolumab|Drug: Cabozantinib   \n",
       "2      Drug: Bevacizumab|Drug: Cetuximab|Drug: Pemetr...   \n",
       "3                    Drug: Fulvestrant with Enzalutamide   \n",
       "4                               Drug: Oxycodone/Naloxone   \n",
       "...                                                  ...   \n",
       "11183                      Drug: Bintrafusp alfa (M7824)   \n",
       "11186  Biological: Brachyury-TRICOM|Drug: Entinostat|...   \n",
       "11190       Drug: Olaparib Pill|Procedure: Prostatectomy   \n",
       "11193            Drug: M7824|Drug: M9241|Radiation: SBRT   \n",
       "11194                        Drug: Triiodothyronine (T3)   \n",
       "\n",
       "                                        Outcome Measures  Gender  \\\n",
       "0      Numerical Rating Scale (NRS)|The Average Dose ...     All   \n",
       "1      Overall Response Rate|Number of Participants W...  Female   \n",
       "2      2-year Progression-free Survival (PFS)|2-year ...     All   \n",
       "3      Clinical Benefit Rate of the Combination of En...  Female   \n",
       "4      Change in Numeric Rating Scales (NRS) Score|Ch...     All   \n",
       "...                                                  ...     ...   \n",
       "11183  Proportion of Participants With an Objective R...     All   \n",
       "11186  Overall Response (Partial Response + Complete ...     All   \n",
       "11190  Number of Participants With Prostate Specific ...    Male   \n",
       "11193  Recommended Phase 2 Dose (RP2D) of NHS-IL12 (M...     All   \n",
       "11194  Number of Participants With Progression-free S...     All   \n",
       "\n",
       "                                                Age           Phases  \\\n",
       "0       18 Years to 80 Years   (Adult, Older Adult)          Phase 3   \n",
       "1         18 Years and older   (Adult, Older Adult)          Phase 2   \n",
       "2         18 Years and older   (Adult, Older Adult)          Phase 2   \n",
       "3      18 Years to 100 Years   (Adult, Older Adult)          Phase 2   \n",
       "4         20 Years and older   (Adult, Older Adult)          Phase 4   \n",
       "...                                             ...              ...   \n",
       "11183     18 Years and older   (Adult, Older Adult)          Phase 2   \n",
       "11186     18 Years and older   (Adult, Older Adult)          Phase 1   \n",
       "11190     18 Years and older   (Adult, Older Adult)          Phase 2   \n",
       "11193     18 Years and older   (Adult, Older Adult)  Phase 1|Phase 2   \n",
       "11194  18 Years to 105 Years   (Adult, Older Adult)          Phase 2   \n",
       "\n",
       "       Enrollment      Funded Bys  \\\n",
       "0             242        Industry   \n",
       "1              18  Other|Industry   \n",
       "2              80  Other|Industry   \n",
       "3              32  Other|U.S. Fed   \n",
       "4             359        Industry   \n",
       "...           ...             ...   \n",
       "11183           2             NIH   \n",
       "11186           1             NIH   \n",
       "11190           1  Other|Industry   \n",
       "11193           3             NIH   \n",
       "11194           7           Other   \n",
       "\n",
       "                                           Study Designs Start Date  \\\n",
       "0      Allocation: Randomized|Intervention Model: Par...     Jan-11   \n",
       "1      Allocation: N/A|Intervention Model: Single Gro...  30-Nov-17   \n",
       "2      Allocation: Randomized|Intervention Model: Sin...     Oct-08   \n",
       "3      Allocation: N/A|Intervention Model: Single Gro...   6-Jul-17   \n",
       "4      Allocation: N/A|Intervention Model: Single Gro...     Jul-12   \n",
       "...                                                  ...        ...   \n",
       "11183  Allocation: N/A|Intervention Model: Single Gro...  26-Oct-20   \n",
       "11186  Allocation: Non-Randomized|Intervention Model:...   4-May-21   \n",
       "11190  Allocation: N/A|Intervention Model: Single Gro...  25-May-18   \n",
       "11193  Allocation: Non-Randomized|Intervention Model:...  15-Jun-21   \n",
       "11194  Allocation: N/A|Intervention Model: Single Gro...   1-Mar-19   \n",
       "\n",
       "      Completion Date  Study Duration (months)  \\\n",
       "0              Jul-12                       18   \n",
       "1           30-Aug-19                       21   \n",
       "2              Sep-14                       71   \n",
       "3           10-Apr-20                       33   \n",
       "4              Apr-14                       21   \n",
       "...               ...                      ...   \n",
       "11183       13-Oct-21                       11   \n",
       "11186       22-Oct-21                        5   \n",
       "11190        7-Dec-21                       42   \n",
       "11193        3-Feb-22                        7   \n",
       "11194        9-Mar-22                       36   \n",
       "\n",
       "                                               Locations  \\\n",
       "0                                                    NaN   \n",
       "1      Dana-Farber Cancer Institute, Boston, Massachu...   \n",
       "2      University of Pittsburgh Medical Center, Pitts...   \n",
       "3      University of Colorado, Aurora, Colorado, Unit...   \n",
       "4      13 sites including Yeungnam University Medical...   \n",
       "...                                                  ...   \n",
       "11183  National Institutes of Health Clinical Center,...   \n",
       "11186  National Institutes of Health Clinical Center,...   \n",
       "11190  Lifespan Cancer Institute: The Miriam and Rhod...   \n",
       "11193  National Institutes of Health Clinical Center,...   \n",
       "11194  Aultman Medical Group Hematology and Oncology,...   \n",
       "\n",
       "                                               URL  \n",
       "0      https://ClinicalTrials.gov/show/NCT01675622  \n",
       "1      https://ClinicalTrials.gov/show/NCT03316586  \n",
       "2      https://ClinicalTrials.gov/show/NCT00703976  \n",
       "3      https://ClinicalTrials.gov/show/NCT02953860  \n",
       "4      https://ClinicalTrials.gov/show/NCT01719757  \n",
       "...                                            ...  \n",
       "11183  https://ClinicalTrials.gov/show/NCT04501094  \n",
       "11186  https://ClinicalTrials.gov/show/NCT04296942  \n",
       "11190  https://ClinicalTrials.gov/show/NCT03432897  \n",
       "11193  https://ClinicalTrials.gov/show/NCT04327986  \n",
       "11194  https://ClinicalTrials.gov/show/NCT03787303  \n",
       "\n",
       "[4839 rows x 18 columns]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_cancer1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "7bb6713a-9ffb-4f1b-b0a2-8124fddd3aca",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Allocation: N/A',\n",
       " 'Intervention Model: Single Group Assignment',\n",
       " 'Masking: None (Open Label)',\n",
       " 'Primary Purpose: Treatment']"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_cancer1['Study Designs'][123].split('|')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "f8b4961f-dabd-4772-a7f1-e65d97817965",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Intervention Model: Single Group Assignment'"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "s = df_cancer1['Study Designs'][123].split('|')[1]\n",
    "s"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "f6eca150-00b1-41e9-a47c-524c5aa41cb0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "' Single Group Assignment'"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "s.split(':')[1:][0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f891a855-25a2-46f1-bef4-2b547f87104f",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "670a293c-73d3-4268-8853-87695009f476",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "b558ef9c-190b-42d5-bafe-caf8e7e45967",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment'"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_cancer1['Study Designs'][377]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "ad92b916-ef3e-4413-be7c-953ba20a27dc",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Alloc =[]\n",
    "# Interv = []\n",
    "# Mask = []\n",
    "# Purp = []\n",
    "# for item in df_cancer1['Study Designs']:\n",
    "#     Alloc_splitted = item.split('|')\n",
    "#         if len(splitted) != 4:\n",
    "            \n",
    "#     Alloc.append(splitted[0].split(':')[1:][0])\n",
    "#     Interv.append(splitted[1].split(':')[1:][0])\n",
    "#     Mask.append(splitted[2].split(':')[1:][0])\n",
    "#     Purp.append(splitted[3].split(':')[1:][0])\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "667f4433-1d27-4db6-a183-be9a824e0bd1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'N/A'"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Alloc =[]\n",
    "for item in df_cancer1['Study Designs']:\n",
    "    if 'Allocation' in item:\n",
    "        Alloc_splitted = item.split('Allocation: ')\n",
    "        Alloc_splitted_more = Alloc_splitted[1].split('|')\n",
    "        Alloc.append(Alloc_splitted_more[0])\n",
    "    else:\n",
    "        Alloc.append('N/A')\n",
    "\n",
    "Alloc[377]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "6ade0424-19ac-4ebd-9d02-2caf4b635c23",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Allocation: N/A|Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Allocation: Randomized|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment\n",
      "Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Allocation: Randomized|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment\n",
      "Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Basic Science\n",
      "Allocation: N/A|Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Masking: None (Open Label)|Primary Purpose: Other\n",
      "Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Basic Science\n",
      "Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Masking: None (Open Label)|Primary Purpose: Treatment\n",
      "Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment\n"
     ]
    }
   ],
   "source": [
    "for item in df_cancer1['Study Designs']:\n",
    "    if 'Intervention Model: ' not in item:\n",
    "        print(item)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "47bd8016-62f9-4342-9155-93b47eb32474",
   "metadata": {},
   "outputs": [],
   "source": [
    "Interv =[]\n",
    "for item in df_cancer1['Study Designs']:\n",
    "    if 'Intervention Model: ' in item:\n",
    "        Interv_splitted = item.split('Intervention Model: ')\n",
    "        Interv_splitted_more = Interv_splitted[1].split('|')\n",
    "        Interv.append(Interv_splitted_more[0])\n",
    "    else:\n",
    "        Interv.append('N/A')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "665cb6da-e4c2-43da-b8df-8e4ccea19b64",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'N/A',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Crossover Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'N/A',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Factorial Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'N/A',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'N/A',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Crossover Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'N/A',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Crossover Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Crossover Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Crossover Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Crossover Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'N/A',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'N/A',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'N/A',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Crossover Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Crossover Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Crossover Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Crossover Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Factorial Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'N/A',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Crossover Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Sequential Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Parallel Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " 'Single Group Assignment',\n",
       " ...]"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Interv"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "fa5e4cbf-59bf-4141-a2bb-1dd5ebf8208f",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Allocation: N/A|Intervention Model: Single Group Assignment\n",
      "Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic\n",
      "Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment\n",
      "Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science\n",
      "Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment\n",
      "Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment\n"
     ]
    }
   ],
   "source": [
    "for item in df_cancer1['Study Designs']:\n",
    "    if 'Masking: ' not in item:\n",
    "        print(item)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "185534c5-85db-4ea0-ae5e-c39354c3c3b4",
   "metadata": {},
   "outputs": [],
   "source": [
    "Mask =[]\n",
    "for item in df_cancer1['Study Designs']:\n",
    "    if 'Masking: ' in item:\n",
    "        Mask_splitted = item.split('Masking: ')\n",
    "        Mask_splitted_more = Mask_splitted[1].split('|')\n",
    "        Mask.append(Mask_splitted_more[0])\n",
    "    else:\n",
    "        Mask.append('N/A')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "a384110a-485b-4081-a3ec-a73ce1b911b6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "6"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "counter = 0\n",
    "for i in Mask:\n",
    "    if i == 'N/A':\n",
    "        counter += 1\n",
    "counter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "a9e863e6-0fe4-40f6-ada7-056c0378db3e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Allocation: N/A|Intervention Model: Single Group Assignment\n",
      "Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)\n",
      "Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)\n",
      "Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)\n",
      "Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)\n",
      "Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)\n",
      "Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)\n",
      "Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)\n",
      "Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)\n",
      "Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)\n",
      "Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)\n",
      "Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)\n",
      "Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)\n",
      "Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)\n",
      "Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)\n",
      "Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)\n",
      "Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)\n",
      "Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)\n",
      "Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)\n",
      "Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)\n",
      "Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)\n"
     ]
    }
   ],
   "source": [
    "for item in df_cancer1['Study Designs']:\n",
    "    if 'Purpose: ' not in item:\n",
    "        print(item)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "e9ad18a6-188a-44c6-986a-f0f4e96fe018",
   "metadata": {},
   "outputs": [],
   "source": [
    "Purp =[]\n",
    "for item in df_cancer1['Study Designs']:\n",
    "    if 'Purpose: ' in item:\n",
    "        Purp_splitted = item.split('Purpose: ')\n",
    "        Purp_splitted_more = Purp_splitted[1].split('|')\n",
    "        Purp.append(Purp_splitted_more[0])\n",
    "    else:\n",
    "        Purp.append('N/A')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "1096e471-428c-4275-89cb-9f0230420142",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Basic Science',\n",
       " 'Device Feasibility',\n",
       " 'Diagnostic',\n",
       " 'Health Services Research',\n",
       " 'N/A',\n",
       " 'Other',\n",
       " 'Prevention',\n",
       " 'Screening',\n",
       " 'Supportive Care',\n",
       " 'Treatment'}"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "x=set(Purp)\n",
    "x"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "a9f146f8-f855-4d6a-9f09-00b037ab62f8",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_cancer1['Allocation'] = Alloc\n",
    "df_cancer1['Intervention Model'] = Interv\n",
    "df_cancer1['Masking'] = Mask\n",
    "df_cancer1['Purpose'] = Purp"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "003b0947-3ee1-4b4e-b0b5-3d6a624ffba5",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>Title</th>\n",
       "      <th>Status</th>\n",
       "      <th>Study Results</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Outcome Measures</th>\n",
       "      <th>Gender</th>\n",
       "      <th>Age</th>\n",
       "      <th>Phases</th>\n",
       "      <th>...</th>\n",
       "      <th>Study Designs</th>\n",
       "      <th>Start Date</th>\n",
       "      <th>Completion Date</th>\n",
       "      <th>Study Duration (months)</th>\n",
       "      <th>Locations</th>\n",
       "      <th>URL</th>\n",
       "      <th>Allocation</th>\n",
       "      <th>Intervention Model</th>\n",
       "      <th>Masking</th>\n",
       "      <th>Purpose</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Immediate-Release Oxycodone Capsules Study in ...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>Drug: Oxycodone|Drug: Morphine</td>\n",
       "      <td>Numerical Rating Scale (NRS)|The Average Dose ...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years to 80 Years   (Adult, Older Adult)</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: Randomized|Intervention Model: Par...</td>\n",
       "      <td>Jan-11</td>\n",
       "      <td>Jul-12</td>\n",
       "      <td>18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01675622</td>\n",
       "      <td>Randomized</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Quadruple (Participant, Care Provider, Investi...</td>\n",
       "      <td>Treatment</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>A Phase II Study of Nivolumab in Combination W...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>Drug: Nivolumab|Drug: Cabozantinib</td>\n",
       "      <td>Overall Response Rate|Number of Participants W...</td>\n",
       "      <td>Female</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>30-Nov-17</td>\n",
       "      <td>30-Aug-19</td>\n",
       "      <td>21</td>\n",
       "      <td>Dana-Farber Cancer Institute, Boston, Massachu...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03316586</td>\n",
       "      <td>N/A</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>Treatment</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Radiation, Cetuximab and Pemetrexed With or Wi...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>Drug: Bevacizumab|Drug: Cetuximab|Drug: Pemetr...</td>\n",
       "      <td>2-year Progression-free Survival (PFS)|2-year ...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: Randomized|Intervention Model: Sin...</td>\n",
       "      <td>Oct-08</td>\n",
       "      <td>Sep-14</td>\n",
       "      <td>71</td>\n",
       "      <td>University of Pittsburgh Medical Center, Pitts...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00703976</td>\n",
       "      <td>Randomized</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>Diagnostic</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Fulvestrant Plus Enzalutamide in ER+/Her2- Adv...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>Drug: Fulvestrant with Enzalutamide</td>\n",
       "      <td>Clinical Benefit Rate of the Combination of En...</td>\n",
       "      <td>Female</td>\n",
       "      <td>18 Years to 100 Years   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>6-Jul-17</td>\n",
       "      <td>10-Apr-20</td>\n",
       "      <td>33</td>\n",
       "      <td>University of Colorado, Aurora, Colorado, Unit...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT02953860</td>\n",
       "      <td>N/A</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>Treatment</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>PROspective Non-interventional Open laBEl Tria...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>Drug: Oxycodone/Naloxone</td>\n",
       "      <td>Change in Numeric Rating Scales (NRS) Score|Ch...</td>\n",
       "      <td>All</td>\n",
       "      <td>20 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 4</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Jul-12</td>\n",
       "      <td>Apr-14</td>\n",
       "      <td>21</td>\n",
       "      <td>13 sites including Yeungnam University Medical...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01719757</td>\n",
       "      <td>N/A</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>Treatment</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11183</th>\n",
       "      <td>11184</td>\n",
       "      <td>A Phase II Study of Bintrafusp Alfa (M7824) in...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Urothelial Cancer</td>\n",
       "      <td>Drug: Bintrafusp alfa (M7824)</td>\n",
       "      <td>Proportion of Participants With an Objective R...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>26-Oct-20</td>\n",
       "      <td>13-Oct-21</td>\n",
       "      <td>11</td>\n",
       "      <td>National Institutes of Health Clinical Center,...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT04501094</td>\n",
       "      <td>N/A</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>Treatment</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11186</th>\n",
       "      <td>11187</td>\n",
       "      <td>BN-Brachyury, Entinostat, Adotrastuzumab Emtan...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Breast Cancer|Triple Negative Breast Cancer|HE...</td>\n",
       "      <td>Biological: Brachyury-TRICOM|Drug: Entinostat|...</td>\n",
       "      <td>Overall Response (Partial Response + Complete ...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>4-May-21</td>\n",
       "      <td>22-Oct-21</td>\n",
       "      <td>5</td>\n",
       "      <td>National Institutes of Health Clinical Center,...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT04296942</td>\n",
       "      <td>Non-Randomized</td>\n",
       "      <td>Sequential Assignment</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>Treatment</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11190</th>\n",
       "      <td>11191</td>\n",
       "      <td>BrUOG 337: Olaparib Prior to Radical Prostatec...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Prostate Cancer|Adenocarcinoma of the Prostate</td>\n",
       "      <td>Drug: Olaparib Pill|Procedure: Prostatectomy</td>\n",
       "      <td>Number of Participants With Prostate Specific ...</td>\n",
       "      <td>Male</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>25-May-18</td>\n",
       "      <td>7-Dec-21</td>\n",
       "      <td>42</td>\n",
       "      <td>Lifespan Cancer Institute: The Miriam and Rhod...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03432897</td>\n",
       "      <td>N/A</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>Treatment</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11193</th>\n",
       "      <td>11194</td>\n",
       "      <td>Immune Checkpoint Inhibitor M7824 and the Immu...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Histologically or Cytologically Confirmed Panc...</td>\n",
       "      <td>Drug: M7824|Drug: M9241|Radiation: SBRT</td>\n",
       "      <td>Recommended Phase 2 Dose (RP2D) of NHS-IL12 (M...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>Phase 1|Phase 2</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>15-Jun-21</td>\n",
       "      <td>3-Feb-22</td>\n",
       "      <td>7</td>\n",
       "      <td>National Institutes of Health Clinical Center,...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT04327986</td>\n",
       "      <td>Non-Randomized</td>\n",
       "      <td>Sequential Assignment</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>Treatment</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11194</th>\n",
       "      <td>11195</td>\n",
       "      <td>Study of Euthyroid Hypothyroxinemia in Metasta...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Metastatic Breast Cancer|Thyroid Dysfunction</td>\n",
       "      <td>Drug: Triiodothyronine (T3)</td>\n",
       "      <td>Number of Participants With Progression-free S...</td>\n",
       "      <td>All</td>\n",
       "      <td>18 Years to 105 Years   (Adult, Older Adult)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>1-Mar-19</td>\n",
       "      <td>9-Mar-22</td>\n",
       "      <td>36</td>\n",
       "      <td>Aultman Medical Group Hematology and Oncology,...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03787303</td>\n",
       "      <td>N/A</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>Treatment</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>4839 rows × 22 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        Rank                                              Title      Status  \\\n",
       "0          1  Immediate-Release Oxycodone Capsules Study in ...   Completed   \n",
       "1          2  A Phase II Study of Nivolumab in Combination W...   Completed   \n",
       "2          3  Radiation, Cetuximab and Pemetrexed With or Wi...   Completed   \n",
       "3          4  Fulvestrant Plus Enzalutamide in ER+/Her2- Adv...   Completed   \n",
       "4          5  PROspective Non-interventional Open laBEl Tria...   Completed   \n",
       "...      ...                                                ...         ...   \n",
       "11183  11184  A Phase II Study of Bintrafusp Alfa (M7824) in...  Terminated   \n",
       "11186  11187  BN-Brachyury, Entinostat, Adotrastuzumab Emtan...  Terminated   \n",
       "11190  11191  BrUOG 337: Olaparib Prior to Radical Prostatec...  Terminated   \n",
       "11193  11194  Immune Checkpoint Inhibitor M7824 and the Immu...  Terminated   \n",
       "11194  11195  Study of Euthyroid Hypothyroxinemia in Metasta...  Terminated   \n",
       "\n",
       "      Study Results                                         Conditions  \\\n",
       "0       Has Results                                             Cancer   \n",
       "1       Has Results                                      Breast Cancer   \n",
       "2       Has Results                                             Cancer   \n",
       "3       Has Results                                      Breast Cancer   \n",
       "4       Has Results                                             Cancer   \n",
       "...             ...                                                ...   \n",
       "11183   Has Results                                  Urothelial Cancer   \n",
       "11186   Has Results  Breast Cancer|Triple Negative Breast Cancer|HE...   \n",
       "11190   Has Results     Prostate Cancer|Adenocarcinoma of the Prostate   \n",
       "11193   Has Results  Histologically or Cytologically Confirmed Panc...   \n",
       "11194   Has Results       Metastatic Breast Cancer|Thyroid Dysfunction   \n",
       "\n",
       "                                           Interventions  \\\n",
       "0                         Drug: Oxycodone|Drug: Morphine   \n",
       "1                     Drug: Nivolumab|Drug: Cabozantinib   \n",
       "2      Drug: Bevacizumab|Drug: Cetuximab|Drug: Pemetr...   \n",
       "3                    Drug: Fulvestrant with Enzalutamide   \n",
       "4                               Drug: Oxycodone/Naloxone   \n",
       "...                                                  ...   \n",
       "11183                      Drug: Bintrafusp alfa (M7824)   \n",
       "11186  Biological: Brachyury-TRICOM|Drug: Entinostat|...   \n",
       "11190       Drug: Olaparib Pill|Procedure: Prostatectomy   \n",
       "11193            Drug: M7824|Drug: M9241|Radiation: SBRT   \n",
       "11194                        Drug: Triiodothyronine (T3)   \n",
       "\n",
       "                                        Outcome Measures  Gender  \\\n",
       "0      Numerical Rating Scale (NRS)|The Average Dose ...     All   \n",
       "1      Overall Response Rate|Number of Participants W...  Female   \n",
       "2      2-year Progression-free Survival (PFS)|2-year ...     All   \n",
       "3      Clinical Benefit Rate of the Combination of En...  Female   \n",
       "4      Change in Numeric Rating Scales (NRS) Score|Ch...     All   \n",
       "...                                                  ...     ...   \n",
       "11183  Proportion of Participants With an Objective R...     All   \n",
       "11186  Overall Response (Partial Response + Complete ...     All   \n",
       "11190  Number of Participants With Prostate Specific ...    Male   \n",
       "11193  Recommended Phase 2 Dose (RP2D) of NHS-IL12 (M...     All   \n",
       "11194  Number of Participants With Progression-free S...     All   \n",
       "\n",
       "                                                Age           Phases  ...  \\\n",
       "0       18 Years to 80 Years   (Adult, Older Adult)          Phase 3  ...   \n",
       "1         18 Years and older   (Adult, Older Adult)          Phase 2  ...   \n",
       "2         18 Years and older   (Adult, Older Adult)          Phase 2  ...   \n",
       "3      18 Years to 100 Years   (Adult, Older Adult)          Phase 2  ...   \n",
       "4         20 Years and older   (Adult, Older Adult)          Phase 4  ...   \n",
       "...                                             ...              ...  ...   \n",
       "11183     18 Years and older   (Adult, Older Adult)          Phase 2  ...   \n",
       "11186     18 Years and older   (Adult, Older Adult)          Phase 1  ...   \n",
       "11190     18 Years and older   (Adult, Older Adult)          Phase 2  ...   \n",
       "11193     18 Years and older   (Adult, Older Adult)  Phase 1|Phase 2  ...   \n",
       "11194  18 Years to 105 Years   (Adult, Older Adult)          Phase 2  ...   \n",
       "\n",
       "                                           Study Designs Start Date  \\\n",
       "0      Allocation: Randomized|Intervention Model: Par...     Jan-11   \n",
       "1      Allocation: N/A|Intervention Model: Single Gro...  30-Nov-17   \n",
       "2      Allocation: Randomized|Intervention Model: Sin...     Oct-08   \n",
       "3      Allocation: N/A|Intervention Model: Single Gro...   6-Jul-17   \n",
       "4      Allocation: N/A|Intervention Model: Single Gro...     Jul-12   \n",
       "...                                                  ...        ...   \n",
       "11183  Allocation: N/A|Intervention Model: Single Gro...  26-Oct-20   \n",
       "11186  Allocation: Non-Randomized|Intervention Model:...   4-May-21   \n",
       "11190  Allocation: N/A|Intervention Model: Single Gro...  25-May-18   \n",
       "11193  Allocation: Non-Randomized|Intervention Model:...  15-Jun-21   \n",
       "11194  Allocation: N/A|Intervention Model: Single Gro...   1-Mar-19   \n",
       "\n",
       "      Completion Date Study Duration (months)  \\\n",
       "0              Jul-12                      18   \n",
       "1           30-Aug-19                      21   \n",
       "2              Sep-14                      71   \n",
       "3           10-Apr-20                      33   \n",
       "4              Apr-14                      21   \n",
       "...               ...                     ...   \n",
       "11183       13-Oct-21                      11   \n",
       "11186       22-Oct-21                       5   \n",
       "11190        7-Dec-21                      42   \n",
       "11193        3-Feb-22                       7   \n",
       "11194        9-Mar-22                      36   \n",
       "\n",
       "                                               Locations  \\\n",
       "0                                                    NaN   \n",
       "1      Dana-Farber Cancer Institute, Boston, Massachu...   \n",
       "2      University of Pittsburgh Medical Center, Pitts...   \n",
       "3      University of Colorado, Aurora, Colorado, Unit...   \n",
       "4      13 sites including Yeungnam University Medical...   \n",
       "...                                                  ...   \n",
       "11183  National Institutes of Health Clinical Center,...   \n",
       "11186  National Institutes of Health Clinical Center,...   \n",
       "11190  Lifespan Cancer Institute: The Miriam and Rhod...   \n",
       "11193  National Institutes of Health Clinical Center,...   \n",
       "11194  Aultman Medical Group Hematology and Oncology,...   \n",
       "\n",
       "                                               URL      Allocation  \\\n",
       "0      https://ClinicalTrials.gov/show/NCT01675622      Randomized   \n",
       "1      https://ClinicalTrials.gov/show/NCT03316586             N/A   \n",
       "2      https://ClinicalTrials.gov/show/NCT00703976      Randomized   \n",
       "3      https://ClinicalTrials.gov/show/NCT02953860             N/A   \n",
       "4      https://ClinicalTrials.gov/show/NCT01719757             N/A   \n",
       "...                                            ...             ...   \n",
       "11183  https://ClinicalTrials.gov/show/NCT04501094             N/A   \n",
       "11186  https://ClinicalTrials.gov/show/NCT04296942  Non-Randomized   \n",
       "11190  https://ClinicalTrials.gov/show/NCT03432897             N/A   \n",
       "11193  https://ClinicalTrials.gov/show/NCT04327986  Non-Randomized   \n",
       "11194  https://ClinicalTrials.gov/show/NCT03787303             N/A   \n",
       "\n",
       "            Intervention Model  \\\n",
       "0          Parallel Assignment   \n",
       "1      Single Group Assignment   \n",
       "2      Single Group Assignment   \n",
       "3      Single Group Assignment   \n",
       "4      Single Group Assignment   \n",
       "...                        ...   \n",
       "11183  Single Group Assignment   \n",
       "11186    Sequential Assignment   \n",
       "11190  Single Group Assignment   \n",
       "11193    Sequential Assignment   \n",
       "11194  Single Group Assignment   \n",
       "\n",
       "                                                 Masking     Purpose  \n",
       "0      Quadruple (Participant, Care Provider, Investi...   Treatment  \n",
       "1                                      None (Open Label)   Treatment  \n",
       "2                                      None (Open Label)  Diagnostic  \n",
       "3                                      None (Open Label)   Treatment  \n",
       "4                                      None (Open Label)   Treatment  \n",
       "...                                                  ...         ...  \n",
       "11183                                  None (Open Label)   Treatment  \n",
       "11186                                  None (Open Label)   Treatment  \n",
       "11190                                  None (Open Label)   Treatment  \n",
       "11193                                  None (Open Label)   Treatment  \n",
       "11194                                  None (Open Label)   Treatment  \n",
       "\n",
       "[4839 rows x 22 columns]"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_cancer1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "b184c672-69ed-43f3-8b23-3016cd884164",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "15\n"
     ]
    }
   ],
   "source": [
    "c=0\n",
    "for item in df_cancer['Outcome Measures']:\n",
    "    if 'NRS' in item or 'Numerical Rating Scale' in item:\n",
    "        c += 1\n",
    "print(c)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
